lymecycline and Arthritis--Reactive

lymecycline has been researched along with Arthritis--Reactive* in 5 studies

Reviews

1 review(s) available for lymecycline and Arthritis--Reactive

ArticleYear
Recent developments in the therapy of spondyloarthropathies.
    Current rheumatology reports, 2000, Volume: 2, Issue:4

    Topics: Alleles; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Reactive; Chronic Disease; Ciprofloxacin; Cyclosporine; Double-Blind Method; Drug Combinations; Follow-Up Studies; Forecasting; Glucosamine; Humans; Immunosuppressive Agents; Lymecycline; Meta-Analysis as Topic; Methotrexate; Multicenter Studies as Topic; Placebos; Polymorphism, Genetic; Randomized Controlled Trials as Topic; Spondylarthropathies; Sulfasalazine; Time Factors; Tumor Necrosis Factor-alpha

2000

Trials

3 trial(s) available for lymecycline and Arthritis--Reactive

ArticleYear
Antibiotic treatment and long term prognosis of reactive arthritis.
    Annals of the rheumatic diseases, 2003, Volume: 62, Issue:7

    To evaluate whether a three month course of lymecycline has an effect on the long term prognosis of reactive arthritis (ReA).. In 1987-88 a double-blind controlled study with three month course of lymecycline/placebo was conducted. 17 of 23 patients treated at the outpatient department of Helsinki University Central Hospital volunteered to take part in a follow up study, where a physical examination were performed, and erythrocyte sedimentation rate, C reactive protein, rheumatoid factor, and radiographs of the lumbosacral spine and sacroiliac joints and of symptomatic peripheral joints were examined.. 16/17 (94%) patients reported some kind of back pain and 10/17 (59%) peripheral joint symptoms during the follow up. Two patients had unilateral grade 1 sacroiliitis, one patient grade 4 sacroiliitis, and one patient bilateral grade 2 sacroiliitis. In one patient the disease had progressed to ankylosing spondylitis (AS), and in another to chronic spondyloarthropathy. In addition, two patients had small erosions in radiocarpal joints. No statistically significant differences were found between placebo and lymecycline groups in the development of chronic arthritis, sacroiliitis, or AS.. The results of the initial study showed that long term treatment with lymecycline in patients with acute ReA decreased the duration of arthritis in those with Chlamydia trachomatis triggered ReA, but not in other patients with ReA. Ten years after the acute arthritis one patient had developed AS, and three had radiological sacroiliitis, three patients had radiological changes at peripheral joints. Long term lymecycline treatment did not change the natural history of the disease.

    Topics: Adult; Anti-Bacterial Agents; Arthritis, Reactive; Double-Blind Method; Female; Follow-Up Studies; Humans; Lymecycline; Male; Middle Aged; Prognosis; Prohibitins; Time Factors

2003
Placebo-controlled study of the effects of three-month lymecycline treatment on serum matrix metalloproteinases in reactive arthritis.
    Annals of the New York Academy of Sciences, 1994, Sep-06, Volume: 732

    Topics: Arthritis, Reactive; Collagenases; Humans; Lymecycline; Placebos; Reference Values; Time Factors

1994
Reactive arthritis. Consider combination treatment.
    BMJ (Clinical research ed.), 1994, May-14, Volume: 308, Issue:6939

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Reactive; Double-Blind Method; Drug Therapy, Combination; Humans; Lymecycline; Middle Aged

1994

Other Studies

1 other study(ies) available for lymecycline and Arthritis--Reactive

ArticleYear
The anticollagenolytic potential of lymecycline in the long-term treatment of reactive arthritis.
    Arthritis and rheumatism, 1992, Volume: 35, Issue:2

    We sought to determine the antiinflammatory properties of lymecycline in the long-term treatment of reactive arthritis (ReA).. Quantitative assay of collagenase activity by densitometry after sodium dodecyl sulfate-polyacrylamide gel electrophoresis.. Therapeutic levels of lymecycline do not directly inhibit the activity of human neutrophil interstitial collagenase, but can prevent the oxidative activation of latent human neutrophil collagenase.. This non-antimicrobial, anticollagenolytic property of lymecycline may contribute to its therapeutic efficacy in the treatment of patients with ReA.

    Topics: Arthritis, Reactive; Enzyme Activation; Humans; In Vitro Techniques; Lymecycline; Microbial Collagenase; Neutrophils; Prohibitins

1992